[1]张 齐,涂建飞,靳 勇,等.新型仿生核壳结构载药微球DiaSphere用于肝癌的安全性和有效性[J].介入放射学杂志,2026,(05):509-513.[doi:10.3969/j.issn.1008-794X.2026.05.008 ]
　ZHANG Qi,TU Jianfei,JIN Yong,et al.The safety and efficacy of novel biomimetic core-shell structure DiaSphere drug-eluting microspheres for the treatment of liver cancer[J].J Intervent Med,2026,(05):509-513.[doi:10.3969/j.issn.1008-794X.2026.05.008 ]
点击复制

新型仿生核壳结构载药微球DiaSphere用于肝癌的安全性和有效性()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2026年05
页码:
509-513
栏目:
肿瘤介入
出版日期:
2026-05-25

文章信息/Info

Title:
The safety and efficacy of novel biomimetic core-shell structure DiaSphere drug-eluting microspheres for the treatment of liver cancer
文章编号:
1008-794X(2026)-005-0509-05
作者:
张 齐;  涂建飞;  靳 勇;  陈文华;  王卫东;  鲁 东;  黄祥忠;  朱 军;  潘 涛;  孙 蓬
210009 江苏南京 东南大学附属中大医院(张 齐、潘 涛); 丽水市中心医院(温州医科大学附属第五医院)(涂建飞); 苏州大学附属第二医院(靳 勇); 苏州大学附属第三医院(陈文华); 南京医科大学附属无锡市人民医院(王卫东); 中国科学技术大学附属第一医院(鲁 东); 江阴江阴市人民医院(黄祥忠); 盐城市第三人民医院(朱 军); 科睿驰(深圳)医疗科技发展有限公司(孙 蓬)
Author(s):
ZHANG Qi; TU Jianfei; JIN Yong; CHEN Wenhua; WANG Weidong; LU Dong; HUANG Xiangzhong; ZHU Jun; PAN Tao; SUN Peng.
Department of Interventional and Vascular Surgery,Affiliated Zhongda Hospital,Southeast University,Nanjing,Jiangsu Province 210009,China
关键词:
肝癌;  药物洗脱微球-经动脉化疗栓塞;  DiaSphere载药微球;  疗效
分类号:
R735.7
DOI:
10.3969/j.issn.1008-794X.2026.05.008
文献标志码:
A
摘要:
目的 探讨新型仿生核壳结构载药微球DiaSphere加载蒽环类药物行药物洗脱微球TACE(drug eluting beads-TACE,DEB-TACE)治疗肝癌的安全性与有效性。方法 选取2022年12月至2023年11月东南大学附属中大医院等8家中心收治的肝癌患者34例,以DiaSphere载药微球加载蒽环类化疗药物行DEB-TACE治疗。治疗后随访3个月,评价抗肿瘤疗效,记录肝功能、并发症及患者预后情况。结果 34例患者均成功实施DEB-TACE治疗,栓塞成功率100%。末次TACE术后1个月、3个月患者客观缓解率分别为67.65%、75.00%。最大靶病灶直径由术前的(31.36±16.72)mm降至末次DEB-TACE术后1个月的(19.73±15.98)mm,差异有统计学意义(P<0.05)。术后30例患者出现不良事件,其中栓塞后综合征27例(79.4%),高血压7例(20.59%),经对症支持治疗后,均在7 d内缓解或消失。未发生与器械相关的不良事件。结论 新型仿生核壳结构载药微球DiaSphere加载蒽环类药物行DEB-TACE治疗肝癌具短期疗效好,安全可行。

参考文献/References:

[1] 姜绍文,周惠娟,谢 青.我国原发性肝癌筛查的现状、挑战及发展方向[J].诊断学理论与实践.2024,23:9-15.
Jiang SW,Zhou HJ,Xie Q.Current status,challenges and future directions for hepatocellular carcinoma surveillance in China[J].J Diagn Concepts Pract,2024,23:9-15.
[2]中国医师协会介入医师分会临床诊疗指南专委会.中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2023年版)[J].中华医学杂志,2023,103:2674-2694.
Clinical Guidelines Committee of Chinese College of Interventionalists.Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma(2023 edition)[J].Nat Med J China,2023,103:2674-2694.
[3]中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024年版)[J].中华肝脏病杂志,2024,32:581-630.
Department of Medical Administration,National Health Commission of the People's Republic of China.Guideline for diagnosis and treatment of primary liver cancer(2024 version)[J].Chin J Hepatolo,2024,32:581-630.
[4]Lencioni R,De Baere T,Soulen MC,et al.Lipiodol transarterial chemoembolization for hepatocellular carcinoma:a systematic review of efficacy and safety data[J].Hepatology,2016,64:106-116.
[5]Han T,Yang X,Zhang Y,et al.The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma:a meta-analysis[J].BioScience Trends,2019,13:374-381.
[6]Katsanos K,Kitrou P,Spiliopoulos S,et al.Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma:a network meta-analysis of randomized controlled trials[J].PLoS One,2017,12:e0184597.
[7]吴 迪,郑 琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33:921-927.
Wu D,Zheng L.Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].J Interv Radiol,2024,33:921-927.
[8]金泓宇,袁 驰,廖明恒,等.载药微球在肝细胞肝癌动脉化疗栓塞治疗中的研究进展[J].中国普外基础与临床杂志,2020,27:232-238.
Jin HY,Yuan C,Liao MH,et al.Research progress of drug-eluting beads in transarterial chemoembolization for hepatocellular carcinoma[J].Chin J Bases Clin Gen Surg,2020,27:232-238.
[9]李 瑞,周 军,于炜婷,等.动脉栓塞微球的研究进展[J].生物医学工程与临床,2023,27:247-252.
Li R,Zhou J,Yu WT,et al.Research progress of arterial embolic microspheres[J].Biomedical Engineering and Clinical,2023,27:247-252.
[10]杨延杰,马靖嶔,颜志平.可视化微球研究进展[J].介入放射学杂志,2024,33(02):115-121.
Yang YJ,Ma JQ,Yan ZP.Research advances in visualized microspheres[J].J Interv Radiol,2024,33:115-121.
[11]胡泽鑫,黄金涛,仲斌演,等.经肝动脉化疗栓塞术及其联合方案治疗肝细胞癌的现状与展望[J].临床肝胆病杂志,2024,40:175-180.
Hu ZX,Huang JT,Zhong BY,et al.Current status and prospects of transarterial chemoembolization and its combined regimens in the treatment of hepatocellular carcinoma[J].J Clin Hepatol,2024,40:175-180.
[12]Lencioni R,De Baere T,Burrel M,et al.Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead(DEBDOX):Technical Recommendations[J].CardioVascular and Interventional Radiology,2012,35:980-985.
[13]Lee SY,Ou HY,Yu CY,et al.Drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma:does size really matter?[J].Diagn Interv Radiol.2020,26:230-235.
[14]Zurstrassen CE,Gireli LPO,Tyng CJ,et al.Safety and efficacy of HepaSphere 50-100 μm in the treatment of hepatocellular carcinoma[J].Minim Invasive Ther Allied Technol,2017,26:212-219.
[15]Bishay VL,Maglione K,Khanna R,et al.Chemoembolization with drug-eluting microspheres(DEM-TACE)for hepatocellular carcinoma:single-center review of safety and efficacy[J].J Hepatocell Carcinoma,2014:187.
[16]Sun J,Zhou G,Xie X,et al.Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization by CalliSpheres in 275 Hepatocellular Carcinoma Patients:Results From the Chinese CalliSpheres Transarterial Chemoembolization in Liver Cancer(CTILC)Study[J].Oncol Res,2020,28:75-94.
[17]Peng Z,Cao G,Hou Q,et al.The comprehensive analysis of efficacy and safety of CalliSpheres drug-eluting beads transarterial chemoembolization in 367 liver cancer patients:a multiple-center,cohort stud[J].Oncol Res,2020,28:249-271.
[18]Albrecht KC,Aschenbach R,Diamantis I,et al.Response rateand safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-μm doxorubicin-eluting microspheres[J].J Cancer Res Clin Oncol,2021,147:23-32.
[19]Qu HY,Wu YN,Yu CY,et al.Transarterial chemoembolization using 100-μm drug-eluting microspheres in patients with hepato-cellular carcinoma:a prospective study and midterm follow-up[J].J Vasc Interv Radiol,2020,31:1784-1791.
[20]龚元川,邵国良.载药微球的理化特性及其在肝癌介入治疗中的应用进展[J].介入放射学杂志,2022,31:616-622.
Gong YC,Shao GL.Physical and chemical properties of drug-eluting beads and its application progress in interventional therapy of hepatocellular carcinoma[J].J Interv Radiol,2022,31:616-622.
(收稿日期:2025-06-24)
(本文编辑:新 宇)

相似文献/References:

[1]曹海利,孟巍,白彬.肝癌基因治疗研究新进展[J].介入放射学杂志,2008,(05):375.
　CAO Haili,MENG Wei,BAI Bin.New progress in research of gene therapy for hepatocellular carcinoma[J].J Intervent Med,2008,(05):375.
[2]陆骊工,胡宝山,李勇,等.中晚期原发性肝癌合并症的介入治疗研究[J].介入放射学杂志,2008,(07):514.
　LU Ligong,HU Baoshan,LI Yong,et al.Study of interventional therapy for complications in advanced primary hepatocellular carcinoma[J].J Intervent Med,2008,(05):514.
[3]杨伟洪,刘鹏程,梁珊瑚,等.多层螺旋CT血管造影在判断肝癌寄生供血中的价值[J].介入放射学杂志,2008,(09):654.
　YANG Weihong,LIU Pengchen g,LIANG Shanhu,et al.Evaluation of MSCTA for parasitic blood supply in hepatic carcinoma[J].J Intervent Med,2008,(05):654.
[4]张茵,周兵,许秀芳,等.肝动脉化疗栓塞治疗原发性肝癌存活２０年一例[J].介入放射学杂志,2008,(09):684.
　ZHANG Yin,ZHOU Bing,XU Xiufang,et al.Survival more than２０years after transarterial chemical embolization for hepatocellular carcinoma：A case report[J].J Intervent Med,2008,(05):684.
[5]官泳松,贺庆.肝癌介入治疗中应用p５３的几个要点[J].介入放射学杂志,2008,(11):761.
　GUAN Yongsong,HE Qing.Essentials in clinical application of p５３for tumors intervention－example of liver cancer[J].J Intervent Med,2008,(05):761.
[6]肖运平,肖恩华.介入治疗在防治肝癌术后复发中的作用及进展[J].介入放射学杂志,2008,(11):831.
　XIAO Yunping,XIAO Enhua.The role and progress of interventional therapy in the prevention and treatment of postoperative hepatocellular carcinoma recurrence[J].J Intervent Med,2008,(05):831.
[7]史震山,陈自谦,杨熙章,等.原发性大肝癌患者TACE后S－腺苷蛋氨酸的护肝作用[J].介入放射学杂志,2008,(11):790.
　SHI Zhenshan,CHEN Ziqian,YANG Xizhang,et al.The clinical study on the liver－protection of S－adenosy－methionine in large hepatocellular carcinoma patients after TACE[J].J Intervent Med,2008,(05):790.
[8]王耀普,杨康健,赵思源,等.兔肝癌模型的改良接种及其DSA影像分析[J].介入放射学杂志,2010,(03):214.
　WANG Yaopu,YANG Kangjian,ZHAO Siyuan,et al.The modified inoculation method for the preparation of rabbit VX２hepatic carcinoma model and DSA imagining observation[J].J Intervent Med,2010,(05):214.
[9]贺洪德,贺晶,罗中华,等.肝动脉化疗栓塞联合门静脉栓塞治疗中晚期肝癌的疗效评价[J].介入放射学杂志,2010,(03):191.
　HE Hongde,HE Jing,LUO Zhonghua,et al.Evaluation of the therapeutic effect of hepatic arterial chemoembolization combined with portal chemoembolization for advanced hepatic carcinomas[J].J Intervent Med,2010,(05):191.
[10]李广琪,曹玮,李超,等.肝动脉热灌注对兔肝VX２肿瘤及正常肝组织血管渗透性功能的作用[J].介入放射学杂志,2010,(03):217.
　LI Guangqi,CAO Wei,LI Chao,et al.Influence of hepatic artery thermotherapy on the vascular permeability of hepatic tumor tissue and normal liver tissue in VX２tumor－bearing rabbits[J].J Intervent Med,2010,(05):217.

备注/Memo

备注/Memo:
通信作者: 张 齐 E-mail:dnzhangqi@126.com
更新日期/Last Update: 2026-05-25